Loading clinical trials...
Loading clinical trials...
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis
Conditions
Interventions
Ataciguat
Placebo
Locations
70
United States
University of Alabama at Birmingham (UAB) - Medical Center
Birmingham, Alabama, United States
Heart Center Research LLC
Huntsville, Alabama, United States
Onyx Clinical Research - Peoria
Peoria, Arizona, United States
Mayo Clinic - Phoenix
Phoenix, Arizona, United States
National Heart Institute
Beverly Hills, California, United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States
Start Date
June 27, 2025
Primary Completion Date
August 31, 2028
Completion Date
September 30, 2030
Last Updated
April 13, 2026
Lead Sponsor
Kardigan, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions